Chart, page-3633

Webinar on now

questions i have put forwards



Have Anp had interaction with the FDA since the original meeting with reference to the tox issue ie are we any closer with regards to them accepting our 6 month trials in both animal studies and the succesful dmd trial and are we likely to hear from the upcoming Ann if this will be clarified in the minutes from the FDA with regards ANps plan to advance through the fda channels

Will ANP advise on the outcome of the pip or have you just moved straight into trial application without informing the market

Wilsons report reveals a $27mil spend for the EMA trial how are we going to fund this

Will ANP advise on the outcome of the pip or have you just moved straight into trial application without informing the market

Would ANP consider an IPO and listing on the NASDAQ to advance 1102 trial through the FDA route

Its early days yet regards the FDA but will ANP consider including Ambulant boys in the trials through the FDA, would appear to be a missed opportunity if you dont, considering these boys that are ambulant at some stage will have an increase in CD49d before becoming none ambulant

See what answers we get if any

See how we go